Tag: CTA
PharmNovo completes drug product manufacturing for Phase IIa study of PN6047
PharmNovo is a clinical-stage pharmaceutical company focused on developing safe and effective drugs for neuropathic pain, an area with significant unmet medical need. The...
PharmNovo secures CTA approval in Spain
PN6047 is a first-in-class small molecule that selectively activates the delta opioid receptor (DOR), avoiding interaction with the mu opioid receptor that is the...